MYO7B

Across TCGA pan-cancer cohorts, MYO7B Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated MYO7B data layer compared with 18 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MYO7B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO7B expression acts as an unfavorable survival marker, although some lineages such as LIHC and UCEC show a favorable association.

CESC, KIRP, and UCS are the cancer types where MYO7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	13	view →
UCS	OS	Median	II,III,IV	0.007	0.616	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.151	0.525	.005	12	view →
READ	OS	Median	III,IV	0.111	0.890	<.001	9	view →
PRAD	DFS	Median	All	0.121	0.890	<.001	6	view →
LIHC	DFS	Median	II,III,IV	1.000	0.197	.020	6	view →
LGG	DFS	Median	All	0.259	0.731	.006	5	view →
UCEC	DFS	Median	All	0.741	0.630	.035	4	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
BRCA	OS	Median	All	0.887	0.963	.038	2	view →
LUSC	OS	Median	All	1.000	0.696	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MYO7B–CESC (DFS)

Open the CESC breakdown →